DNLI

Denali Therapeutics (DNLI)

About Denali Therapeutics (DNLI)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Details

Daily high

$20.61

Daily low

$19.94

Price at open

$20.37

52 Week High

$26.18

52 Week Low

$10.57

Market cap

2.9B

Dividend yield

0.00%

Volume

2.0M

Avg. volume

1.5M

P/E ratio

-6.86

Denali Therapeutics News